PEPTIDESTAT
InvestigationalClinical / approved drugOralEvidence 2/5

Larazotide

Also known as: Larazotide acetate, AT-1001

An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.

Read guideBuy / compare source
Larazotide
Drug class
Tight-junction regulator / zonulin antagonist
Primary targets
Zonulin / tight junctions
Dose reference
Investigational; 0.5 mg orally three times daily in trials
Half-life
Minimal systemic absorption (gut-restricted)
Developer / origin
Alba Therapeutics / 9 Meters Biopharma
Reference year
2005
Evidence score
2/5 - Investigational — failed pivotal trial
Evidence 2/5

Investigational — failed pivotal trial

Larazotide showed positive phase 2 symptom data at the low 0.5 mg dose, but the pivotal phase 3 CeDLara trial was discontinued for futility in 2022 and it is not approved.

Mostly animal, ex vivo, cell, or indirect evidence.

Evidence basis

  • Phase 2b trial in 342 adults met its primary endpoint only at the 0.5 mg dose
  • Gluten-challenge trials showed reduced gluten-induced symptoms at low doses
  • Phase 3 CeDLara halted for futility (2022)
  • Tolerability comparable to placebo; no regulatory approval

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Larazotide guides

Read the matching guide or adjacent research pages for more context.

Larazotide Peptide: Zonulin Antagonist and Celiac TrialsLarazotide is an oral, gut-restricted tight-junction regulator that reached Phase 3 for celiac disease before the pivotal CeDLara trial was halted for futility.Abaloparatide Peptide: Tymlos, PTHrP Analog Uses and Safety LimitsAbaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm LaborAtosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.Bivalirudin Peptide: Angiomax Direct Thrombin Inhibitor GuideBivalirudin is an FDA-approved, hirudin-derived bivalent direct thrombin inhibitor used as a short-acting intravenous anticoagulant during percutaneous coronary intervention.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Lanreotide

Somatuline Depot, Somatuline Autogel

5/5
Clinical / approved drugApproved

Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.

DetailsGuide

Teriparatide

Forteo, Bonsity, PTH 1-34

4/5
Clinical / approved drugApproved

Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.

DetailsGuide
4/5
Clinical / approved drugApproved

Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.

DetailsGuide

Calcitonin

Miacalcin, Fortical, salmon calcitonin

3/5
Clinical / approved drugApproved

Calcitonin activates the calcitonin receptor on osteoclasts to inhibit bone resorption and lower blood calcium, with additional actions on the kidney and gastrointestinal tract.

DetailsGuide

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.